阿托伐他汀联合曲美他嗪治疗冠心病的有效性及安全性分析  

Efficacy and Safety of Atorvastatin Combined with Trimetazidine in the Treatmentof Coronary Heart Disease

作　　者：黄嘉利 关灵[1] 陈丽华[2] 江丽华[1] HUANG Jiali;GUAN Ling;CHEN Lihua;JIANG Lihua(Office of Drug Clinical Trials Institute,Dongguan People's Hospital,Dongguan,Guangdong Province,523000 China;Department of Cardiovascular Medicine,Dongguan People's Hospital,Dongguan,Guangdong Province,523000 China)

机构地区：[1]东莞市人民医院药物临床试验机构办公室,广东东莞523000 [2]东莞市人民医院心血管内科,广东东莞523000

出　　处：《世界复合医学》2022年第7期191-193,198,共4页World Journal of Complex Medicine

摘　　要：目的回顾性分析冠心病患者施行阿托伐他汀联合曲美他嗪治疗的效果。方法随机抽取2018年10月-2019年10月东莞市人民医院收治的106例冠心病患者为观察对象,结合治疗方法不同将其分为对照组(50例,应用阿托伐他汀治疗)、观察组(56例,应用阿托伐他汀联合曲美他嗪治疗)。对比两组心功能指标[左室舒张末期内径(left ventricular end diastolic dimension,LVEDD)、左心室射血分数(left ventricular ejection fraction,LVEF)]、炎症因子水平[超敏C反应蛋白(hypersensitive Creactive protein,hs-CRP)]、再住院率及不良反应发生率。结果观察组治疗后LVEDD(48.24±2.46)mm较对照组更低,且LVEF(49.40±3.85)%较对照组更高,差异有统计学意义(t=11.144、5.050,P<0.05);观察组治疗后hs-CRP(2.52±0.23)mg/L低于对照组,差异有统计学意义(t=47.414,P<0.05);观察组治疗后再住院率(1.79%)较对照组(12.00%)更低,差异有统计学意义(χ^(2)=4.468,P<0.05);观察组不良反应发生率(5.36%)低于对照组(24.00%),差异有统计学意义(χ^(2)=5.516,P<0.05)。结论对冠心病患者采取阿托伐他汀联合曲美他嗪治疗有助于增强疗效,减轻炎症反应,改善心功能,且安全性更高。Objective To retrospectively analyze the effect of atorvastatin combined with trimetazidine in patients with coronary heart disease.Methods A total of 106 patients with coronary heart disease admitted to Dongguan People’s Hospital from October 2018 to October 2019 were randomly selected as the observation subjects. Combined with different treatment methods, they were divided into control group(50 cases,treated with atorvastatin) and observation group(56 cases, treated with atorvastatin combined with trimetazidine). The cardiac function indexes [left ventricular end diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF)], inflammatory factor level [hypersensitive Creactive protein(hs-CRP)], rehospitalization rate and adverse reaction rate were compared between the two groups Results After treatment,the LVEDD(48.24±2.46) mm in the observation group was lower than that in the control group, and the LVEF(49.40±3.85)% was higher than that in the control group, and the difference was statistically significant(t=11.144, 5.050, P<0.05). After treatment, the hs-CRP(2.52±0.23)mg/L in the observation group was lower than that in the control group, and the difference was statistically significant(t=47.414,P<0.05).The rate of rehospitalization in the observation group(1.79%) was lower than that in the control group(12.00%), and the difference was statistically significant(χ^(2)=4.468,P<0.05). The incidence of adverse reactions in the observation group(5.36%) was lower than that in the control group(24.00%), and the difference was statistically significant(χ^(2)=5.516,P<0.05). Conclusion The treatment of atorvastatin combined with trimetazidine in patients with coronary heart disease can help to enhance the efficacy, reduce inflammation, improve cardiac function, and has higher safety.

关 键 词：冠心病 阿托伐他汀 曲美他嗪 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]